协和医学杂志

2012, v.3(02) 154-161

[打印本页] [关闭]
本期目录(Current Issue) | 过刊浏览(Past Issue) | 高级检索(Advanced Search)

倍他米松对变应性鼻炎小鼠嗅觉障碍的干预作用
Effectiveness of Betamethasone in Treating Mice with Olfactory Dysfunction from Allergic Rhinitis

王晓巍;倪道凤;朱莹莹;亓放;高志强;陈晓巍;
WANG Xiao-wei,NI Dao-feng,ZHU Ying-ying,QI Fang,GAO Zhi-qiang,CHEN Xiao-wei Department of Otorhinolaryngology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College,Beijing 100730,China

摘要(Abstract):

目的观察变应性鼻炎(allergic rhinitis,AR)对嗅觉功能的影响及倍他米松对AR嗅觉障碍的干预效果。方法应用卵清蛋白致敏并激发BALB/C小鼠,建立AR小鼠模型。应用埋藏小球实验(buried food test,BFT)评估AR小鼠嗅觉功能,HE染色及免疫组化方法观察AR小鼠嗅黏膜组织形态学变化及嗅觉标记蛋白(olfactory marker protein,OMP)表达的变化。腹腔内注射复方倍他米松,分别在干预后第7及14天应用免疫组化方法检测AR小鼠嗅黏膜OMP表达的变化。结果对成功建模的AR小鼠进行嗅觉功能评估,74.55%的AR小鼠伴有嗅觉障碍。AR小鼠嗅黏膜上皮层较对照组明显变薄,嗅感受神经元(olfactory receptor neurons,ORNs)层数减少、排列紊乱。AR小鼠嗅黏膜OMP表达亦较对照组减少,其中AR伴嗅觉障碍组嗅上皮OMP染色阳性细胞数为39.77±2.012,与对照组66.38±1.517比较,差异有统计学意义(P<0.05);但AR不伴嗅觉障碍组嗅上皮OMP染色阳性细胞数为59.50±0.558,与对照组比较差异无统计学意义(P>0.05)。复方倍他米松干预1组小鼠嗅黏膜OMP表达增加,已接近对照组水平,为62.04±1.227,与不用药组47.34±1.809比较差异有统计学意义(P<0.05)。复方倍他米松干预2组OMP表达与复方倍他米松干预1组相似,两组OMP染色阳性细胞数比较差异无统计学意义(P>0.05)。结论 AR引起嗅觉障碍的作用机制除鼻腔气道阻塞原因外,嗅黏膜本身因炎症发生变化也是重要原因。全身应用糖皮质激素可对嗅黏膜产生影响,是治疗AR引发嗅觉障碍的有效方法 。
Objective To explore the impact of allergic rhinitis (AR) on olfactory function and observe the effectiveness of betamethasone in treating mice with olfactory dysfunction.Methods Mouse AR models were established by intraperitoneal injection and intranasal application of ovalubumin.The olfactory function of the mice was evaluated by buried food test (BFT).The expression of olfactory marker protein (OMP) in the olfactory mucosa was tested by immunohistochamistry.The expression of OMP in the olfactory mucosa was observed 7 and 14 days after intraperitoneal application of betamethasone.Results The incidence of olfactory dysfunction in AR mice was 74.55%.The olfactory epithelium became thinner in AR mice than in control group.The down-regulation of OMP in olfactory epithelium was observed in AR mice compared with control group.The number of OMP-positive cells was 66.38±1.517 in control group and 59.50±0.558 in group without olfactory dysfunction (P>0.05).The number of OMP-positive cells was 39.77±2.012 in group with olfactory dysfunction,which was significantly different compared with control group and the group with olfactory dysfunction (P<0.05).The number of OMP-positive cells was 62.04±1.227 in betamethasone group 1,which was significantly higher than that in the non-medication group (47.34±1.809) (P<0.05);meanwhile,it showed no significant difference between betamethasone group 1 and the control group (P>0.05).The number of OMP-positive cells was 63.82±1.254 in betamethasone group 2,and the expression of OMP in betamethasone group 2 was similar to that in betamethasone group 1.Conclusions AR-associated olfactory dysfunction is not only due to the blockage of nasal cavity but also the change in mucosa by inflammation.Systemic application of betamethasone is an effective method in treating AR-associated olfactory dysfunction.

关键词(KeyWords): 变应性鼻炎;嗅觉;糖皮质激素;嗅觉标记蛋白;动物模型
allergic rhinitis;olfactory;glucocorticoid;olfactory marker protein;animal model

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 王晓巍;倪道凤;朱莹莹;亓放;高志强;陈晓巍;
WANG Xiao-wei,NI Dao-feng,ZHU Ying-ying,QI Fang,GAO Zhi-qiang,CHEN Xiao-wei Department of Otorhinolaryngology,Peking Union Medical College Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College,Beijing 100730,China

Email:

DOI:

参考文献(References):

扩展功能
本文信息
服务与反馈
本文关键词相关文章
本文作者相关文章
中国知网
分享